Antazoline was administered in sixty-five episodes of various types of cardiac arrhythmia.
Introduction
Following the reports of Graham (1947) and Craver, Barrett & Cameron (1951) antazoline 2-(N-benzylanilinomethyl)-2-imidazoline was introduced as an antihistamine and still is in use though almost completely replaced by newer antihistamines. Dutta (1948) reported that antazoline antagonized the depressant action of acetycholine on rabbit atrium and decreased the maximum rate of electrical stimulation to which atrial muscle could respond. Furthermore, it appeared to be about twice as potent as quinidine in its ability to prolong the refractory period of the atrium.
In 1952, McKechnie first demonstrated a great reduction in the number of ventricular premature contractions in man after intravenous and oral antazoline. Brown (1962) demonstrated the effectiveness of antazoline in the prevention of ventricular fibrillation during cooling and rewarming experiments in dogs. Dreifus, Rabbino & Watanabe (1963) reported in their study of 143 episodes of arrhythmia that antazoline was effective in the suppression of atrial and ventricular premature systoles and useful in the termination of paroxysmal atrial and ventricular tachycardia. However, the drug was found to be ineffective in atrial flutter and fibrillation.
Further clinical studies by Reynolds, Baird & Clifford (1964) , Kiger (1964) , Herbst (1965) and Herrmann et al. (1964) In all other cases antazoline hydrochloride was administered by mouth first in doses of 100 mg 4-hourly; if this regimen was not effective within 24 hr, the dose was increased to 200 mg every 4 hr for a further six doses and further increased to 300 mg every 4 hr in unsuccessful cases. Absence of response to this dosage within 24 hr was taken as failure.
The effectiveness of antazoline was considered good when all ectopic beats were abolished or an ectopic tachycardia had been converted to sinoatrial rhythm. The results were recorded as satisfactory when 70% of the ectopic beats had been cleared and when an interrupted paroxysm had not recurred within 12 hr. After the arrhythmia had been converted, antazoline was administered in the same doses for 48 hr and then reduced to half for another 48 hr and then suspended.
Results
Sixty-five episodes of various cardiac arrhythmias in fifty-six patients were included in the present series. There were thirty-one males and twenty-five females, with ages ranging from 13 to 65 years, mean 40-2. As shown in Table 1 there were six episodes of premature atrial systoles, twenty-four episodes of premature ventricular systoles, fifteen of paroxysmal supraventricular tachycardia, ten of auricular fibrillation and ten of ventricular tachycardia. Out of fifty-six patients, fifty had organic heart disease; of these, twenty-five had rheumatic heart disease, twenty had acute myocardial infarction, four had congenital heart disease and one had thyrotoxic heart disease. Two cases developed a cardiac arrhythmia as a terminal event in uraemia with hyperkalemia and two patients developed supraventricular tachycardia postoperatively.
In six patients with atrial premature beats, complete suppression was obtained in five ( Fig. 1) and ectopic contractions were reduced by 70% in the remaining one.
Of twenty-four episodes of ventricular premature beats, twenty-one were completely suppressed within 24 hr (Fig. 2) while there was 70% suppression in three. Following the withdrawal of antazoline there was a recurrence in only two patients, both of whom were suffering from myocardial infarction. Antazoline was re-administered and premature beats were again eliminated. All the fourteen episodes of ventricular premature beats due to digitalis responded to antazoline.
Conversion to regular sinus rhythm in the present series was achieved in seven out of ten and four out of five episodes of paroxysmal atrial and nodal tachycardia respectively (Fig. 3) . One case of paroxysmal atrial tachycardia with thyrotoxic heart disease did not respond to antazoline, while there was a recurrence in one case after 48 hr when the antazoline dosage was halved.
All the patients who had atrialfibrillation demonstrated no significant change in ventricular rate. The atrial mechanism remained unchanged and in no case was sinus rhythm restored. All these cases had atrial fibrillation of more than 3 years' duration.
Termination of paroxysmal ventricular tachycardia by intravenous administration of antazoline phosphate was fairly successful (Fig. 4) was reduced to less than 30/min and QRS complexes were widened to more than 0-16 sec with tall T waves.
The side-effects observed were nausea, vomiting and drowsiness. Nausea and vomiting were more common when the drug was taken on an empty stomach. Drowsiness was another common sideeffect particularly when the dose was more than 800 mg/day. Of the fifty-six patients studied, ten reported these side-effects. They were not serious enough to warrant the withdrawal of the drug.
Discussion
The reported results with antazoline in the various types of cardiac arrhythmias are compared in Table  2 (Kline et al., 1962; Dreifus et al., 1963; Kiger, 1964; Herrmann et al., 1964; Srinivas & Antani, 1971; Antani, 1971 Kiger (1964) and Herrmann et al. (1964) . Recently Srinivas & Antani (1971) action of acetylcholine (Dutta, 1948) and has a mild adrenergic-blocking action (Dreifus et al. 1964 ). Antazoline increased peripheral vascular resistance and decreased both stroke volume and cardiac output. These two latter properties are useful for the maintenance of mean blood pressure.
